Raul R. Rodriguez - Jan 26, 2023 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
CEO, President, Director
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Stock symbol
RIGL
Transactions as of
Jan 26, 2023
Transactions value $
$0
Form type
4
Date filed
1/30/2023, 08:45 PM
Previous filing
Dec 30, 2022
Next filing
Jan 25, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (right to buy) Award $0 +200K +100% $0.00 400K Jan 26, 2023 Common Stock 200K $2.42 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted an option with a performance-based condition with respect to 200,000 shares of common stock on January 24, 2022. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On January 26, 2023, it was determined that the performance metric had been met.
F2 The option was fully vested on January 26, 2023, the date the determination was made that the performance metric had been met.